Pneumococcal meningitis in a patient with severe COVID-19 on dexamethasone and tocilizumab: A case report.

Yoshiaki Murayama, Tomohiko Ishimine, Mikio Sasano, Takafumi Todaka, Takashi Matsumoto, Taiga Shimabukuro, Risa Yonaha

Open access · goldAbstract readCase Reports

In one paragraph

Article in IDCases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.2field-weighted citation impact, top 46% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yoshiaki MurayamaDepartment of Respiratory Medicine, Nakagami Hospital, 610 Noborikawa, Okinawa city, Okinawa 904-2142, Japan.

Tomohiko IshimineDepartment of Respiratory Medicine, Nakagami Hospital, 610 Noborikawa, Okinawa city, Okinawa 904-2142, Japan.

Mikio SasanoDepartment of Critical Care Medicine, Nakagami Hospital, 610 Noborikawa, Okinawa city, Okinawa 904-2142, Japan.

Takafumi TodakaDepartment of Critical Care Medicine, Nakagami Hospital, 610 Noborikawa, Okinawa city, Okinawa 904-2142, Japan.

Takashi MatsumotoDepartment of Critical Care Medicine, Nakagami Hospital, 610 Noborikawa, Okinawa city, Okinawa 904-2142, Japan.

Taiga ShimabukuroDepartment of Respiratory Medicine, Nakagami Hospital, 610 Noborikawa, Okinawa city, Okinawa 904-2142, Japan.

Risa YonahaDepartment of Respiratory Medicine, Nakagami Hospital, 610 Noborikawa, Okinawa city, Okinawa 904-2142, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although various therapeutic agents have been tried for coronavirus disease-2019 (COVID-19) and evidence has accumulated, the risk of secondary infection is increased by underlying disease and immunosuppressive drugs. We report a case of pneumococcal meningitis in a patient with severe COVID-19 who was receiving dexamethasone and tocilizumab. The patient's symptoms improved with appropriate diagnosis and antimicrobial therapy, and she fortunately returned to society without any neurological sequelae of meningitis.

Indexed as

COVID-19MeningitisSARS-CoV-2Secondary-infectionStreptococcus pneumoniaeTocilizumab

Identifiers

PMID36896031

DOI10.1016/j.idcr.2023.e01727

PMCPMC9981263

OpenAlexW4322761293

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.